EUCTR2007-006532-66-FR进行中（未招募）1 期
An open-label, single-arm, phase IV study assessing the immunogenicity and safety of ZOSTAVAX? at minimum release specification approaching expiry potency in subjects =50 years old
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject of either gender aged =50 years on day of signing informed consent
- •2.Positive history of varicella or residence for >30 years in a country with endemic VZV infection
- •3.Subject affiliated to a health social security system
- •4.Subject having signed the informed consent form prior to any study procedure
- •5.Subject able to attend all scheduled visits and to comply with all study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subject febrile (oral temperature =38.3°C) within 72 hours prior to vaccination
- •2.Subject with a prior history of Herpes Zoster clinically diagnosed by a physician
- •3.Subject has previously received a varicella or zoster vaccine
- •4.Exposure to varicella or herpes-zoster within 4 weeks prior to vaccination by:
- •continuous household contact, or
- •non household contact (generally >1 hour of exposure indoors), or
- •hospital contact (in same 2- to 4-bed room or adjacent beds in a large ward or face-to-face contact with an infectious staff member or subject), or
- •contact with a newborn whose mother had onset of varicella 5 days or less before delivery or within 48 hours after delivery
- •5.Subject received any other live virus vaccine within 4 weeks prior to vaccination, or is expected to receive any other live virus vaccine during the study
- •6.Subject received any inactivated vaccine within 14 days prior to vaccination, or is expected to receive any inactivated vaccine during the study
- •7.Subject is treated with immunoglobulins or any blood products, other than autologous blood transfusion, given during the 5 months prior to vaccination or expected during the study
- •8.Subject is taking any nontopical antiviral therapy with activity against herpesviruses, (including but not limited to acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, cidofovir, brivudine)
- •9.Subject is on immunosuppressive therapy:
- •Subjects on corticosteroids should be excluded if they are receiving or are expected to receive, in the period from 4 weeks prior to vaccination until the end of the study, systemic doses greater than required for physiological replacement, i.e., >5 mg of prednisone (or equivalent) for >2 weeks.
- •Excluded immunosuppressive therapies also involve chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation.
- •10.Subject has known or suspected immune dysfunction that is caused by a medical condition, or any other cause. Examples of medical conditions associated with immune dysfunction include congenital immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, or generalized malignancy
- •Note: Subjects with prostate or breast cancer who are not on chemotherapeutic drugs (other than hormone blocking drugs), subjects with skin cancer who are not receiving radiation therapy or chemotherapy, and subjects with a history of other malignancies who have been disease-free for at least 5 years will be eligible for enrollment.
- •11.Subject has a history of hypersensitivity reaction or anaphylactoid reaction to any vaccine component, including gelatin or neomycin
- •12.Subject with known active tuberculosis
- •13.Subject with significant underlying illness preventing completion of the study
- •14.Subject is currently participating or has participated in a study with an investigational compound or device within 4 weeks of signing informed consent.
- •15.Subject is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence
- •16.Any other reason that in the opinion of the investigator might interfere with the study
- •17.Volunteer having been paid more than 4500€ to take part in biomedical researches over the previous 12 months
研究者
相似试验
进行中（未招募）
1 期
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 19.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-PLBoehringer Ingelheim RCV GmbH & Co KG282
进行中（未招募）
1 期
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 17.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-ROBoehringer Ingelheim RCV GmbH & Co KG70
进行中（未招募）
1 期
Darunavir/ritonavir and rilpivirine in therapy-naïve patients.HIV-1EUCTR2012-002663-10-GBSt Stephen's AIDS Trust36
已完成
4 期
A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants Receiving Emetogenic ChemotherapySymptomen en algemene pathologieChemotherapy-Induced Nausea and VomitingNL-OMON48224Merck Sharp & Dohme (MSD)6
进行中（未招募）
1 期
Three-day Fosaprepitant Regimen CINV Safety Study in Pediatric ParticipantsPrevention of Chemotherapy-Induced Nausea and Vomiting (CINV)MedDRA version: 21.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-004844-43-GRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100